The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. immunology market.” Lebwohl, MD, Professor and Systemn Chaior of Dermatology at Icahn School of Medicine at Mount Sinai in New York, NY.

Portfolios 69

Portfolios Injections Office Safety 69

The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections 68

Injections Medical Portfolios Branding 68

The Dermatology Digest

NOVEMBER 14, 2024

Regulatory filings in other markets are underway. In addition, the Swiss approval is supported by the results from the head-to-head DELTA FORCE Phase 3 clinical trial, which evaluated the efficacy and safety of delgocitinib cream compared with oral alitretinoin capsules. The cream is fast-tracked by the U.S. .”

Marketing 36

Marketing Eczema Safety Clinic 36

The Dermatology Digest

FEBRUARY 26, 2024

Marketing Authorization Application. About the MIRA trial The MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody sonelokimab, administered subcutaneously, in the treatment of adult patients with active moderate-to-severe hidradenitis suppurativa.

Office 74

Office Clinic Safety Innovations 74

The Dermatology Digest

FEBRUARY 26, 2024

Swierk noted that the research on the safety implications of tattoos is still out. Regulation of tattoo inks on the American market is very recent. The tattoo inks available in the American and European markets differ because the latter is subject to stricter regulations, overseen by the European Chemicals Agency.

Ingredients 74

Ingredients Marketing Safety Dermatology 74

The Dermatology Digest

APRIL 23, 2024

The CRL did not identify any deficiencies related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical data to support the approval of pz-cel. The BLA for pz-cel was accepted for filing and granted priority review designation by the FDA in November 2023.

Marketing 36

Marketing Safety Clinic Sustainability 36

The Dermatology Digest

MARCH 22, 2024

1,2 Benzene has become a more recent focus of attention related to safety concerns, with an increase in independent product testing and also updated regulations by the Food and Drug Administration related to benzene. Public safety is the first priority of the AARS. Right now, there are many questions about this issue.

Rosacea 64

Rosacea Document Safety Ingredients 64

The Beauty Brains

MAY 13, 2019

The Beauty Brains episode 182 – we cover beauty questions about BB glow facials The safety of self tanners Doing you own research and Hard water and your beauty products Beauty Science News Butt Masks Is natural deodorant necessary ? So, with the uncertain safety profile and the limited benefit I’m not sure I can recommend doing this.

Safety 40

Safety Facials Injections Ingredients 40

The Dermatology Digest

SEPTEMBER 9, 2024

“China has always been a strategic market for Sisram, and the approval of Daxxify serves as a key milestone for bringing Sisram’s high-end injectables portfolio to Mainland China,” says Mr. .” The post TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

FEBRUARY 16, 2024

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

DECEMBER 20, 2023

Before Harbor Health, he led product and go-to-market functions for CVS’s kidney care and home business units. Secondary measures of efficacy, as well as safety and pharmacokinetics, will also be assessed. is a Professor of Dermatology and Director of Dermatologic Surgery at the University of Minnesota.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

JUNE 14, 2024

Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD. ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

FEBRUARY 27, 2024

While both low-concentration and high-concentration strength biosimilars of Humira are marketed in the U.S. We strongly believe that biosimilars are important in addressing inflationary pressures in the healthcare system across all markets, especially in the U.S. Both Alvotech and Teva expect to launch SIMLANDI in the U.S.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to Stelara in patients with moderate to severe psoriasis vulgaris. This marks the fourth FDA-approved biosimilar for Stelara. and worldwide.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

West Lake Dermatology

JANUARY 10, 2025

This comprehensive guide will help you recognize red flags, ask the right questions, and prioritize your safety. In the US, legitimate practitioners often hold certifications from reputable organizations like the American Board of Plastic Surgery (ABPS) or American Academy of Dermatology (AAD).

Legal 36

Legal Injections Safety Ethics 36

The Dermatology Digest

JULY 22, 2024

Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

The Dermatology Digest

MAY 23, 2024

Kimball, MD, MPH, Beth Israel Deaconess Medical Center and Professor of Dermatology, Harvard Medical School, Boston, MA. “In The safety profile of bimekizumab was consistent with safety data seen in previous trials with no new observed safety signals. The primary endpoint in both trials was HiSCR50 at Week 16.

Sustainability 36

Sustainability Safety Clinic Medical 36

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients. The company is currently preparing for Phase 2/3 trials with anticipated initiation in 1Q 2025.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

JULY 10, 2024

Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

MARCH 11, 2024

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. No new safety signals were observed in this trial. The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

FEBRUARY 13, 2024

MediWound Ltd’s EscharEx bested market leader collagenase Santyl ointment in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU). The safety profile and overall incidence of adverse wound reactions were comparable between arms. days for EscharEx vs. 76.0

Safety 36

Safety Marketing Office Clinic 36

Texas Dermatology

DECEMBER 24, 2024

To help you maximize your results, Texas Dermatology is sharing the top 3 tips for effective laser hair removal aftercare. At Texas Dermatology we want our patients to achieve the best possible results, which is why we use the Candela GentleMax Pro Plus.

Hair Removal 36

Hair Removal Waxing Moisturization Med Spa 36

The Dermatology Digest

MARCH 20, 2024

Starting at this year’s Miami Open, La Roche-Posay will have a Sun Safety Booth located on the Tennis Oasis, two additional sampling kiosks at key entry points, while also providing sunscreen to players and staff on the grounds. The Miami Open is taking place from March 17 to March 31 at Hard Rock Stadium in Miami Gardens, Florida.

Branding 36

Branding Partnerships Safety Dermatology 36

West Lake Dermatology

JANUARY 30, 2024

The market has seen a surge in at-home laser hair removal devices offering users the convenience of performing the treatment in the comfort of their homes. Safety should always be a top priority when considering any form of laser treatment. Professional laser hair removal achieves 95%+ hair removal within 7-9 sessions.

Hair Removal 36

Hair Removal Safety Technology Waxing 36

The Dermatology Digest

NOVEMBER 15, 2024

Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world. ICP-332 achieved multiple efficacy endpoints in the China Phase II study for the treatment of patients with moderate-to-severe AD and demonstrated a good safety profile, the Company reported.

Dermatitis 36

Dermatitis Safety Marketing Dermatology 36

The Dermatology Digest

JUNE 10, 2024

Marketing Authorization Application. Two global, randomized, double blind, placebo-controlled trials are planned (IZAR-1 and IZAR-2) to evaluate the efficacy and safety of the nanobody sonelokimab over one year.

Office 36

Office Safety Marketing Dermatology 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Remember, your health and safety are worth every penny spent on genuine Botox treatments. Counterfeit Botox is not merely ineffective; it’s potentially life-threatening as well.

Office 36

Office Surgery Safety Injections 36

The Dermatology Digest

JANUARY 4, 2024

The clinical results demonstrated that DMB-3115 and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of quality, safety and efficacy. market during the next five years. Accord BioPharma is planning to introduce several additional biosimilars to the U.S.

Pharmaceutical 36

Pharmaceutical Partnerships Clinic Safety 36

The Dermatology Digest

MAY 15, 2024

alone and no FDA approved therapies, common warts represent one of the largest unmet needs in all of dermatology. seeking Food and Drug Administration approval for the use of YCANTH for the treatment of common warts, but may also be utilized by Verrica to seek future marketing authorizations in territories outside the U.S.

Pharmaceutical 36

Pharmaceutical Clinic Sales Dermatology 36

Art of Dermatology

SEPTEMBER 6, 2023

Everyone from hotels to oil companies has participated in greenwashed marketing. When fraudulent, deceptive, or even just exaggerated environmental, health, and safety claims are made in the marketing of a product, that’s greenwashing. What is Greenwashing? Greenwashing is not a new tactic.

Branding 36

Branding Skincare Brands Skincare Ingredients 36

The Dermatology Digest

MARCH 6, 2024

Benzoyl Peroxide-based acne medications can become unstable and form benzene, a known human carcinogen, according to new research from Valisure, an independent laboratory focused on testing the purity and safety of pharmaceutical drugs and consumer products. Food and Drug Administration (FDA).

Sanitation 36

Sanitation Pharmaceutical Marketing Safety 36

Eminence Organics

OCTOBER 31, 2023

These days, there are a lot of facial steamers on the market, but you can also DIY at home with a big bowl or sink of warm water and a towel. Robinson says: “Heat and steam are known triggers for many dermatologic conditions, such as rosacea, melasma and eczema.” Visit your nearest Eminence Organics Spa Partner to find out more.

Facials 66

Facials Sebum Hydration Moisturization 66

Eminence Organics

OCTOBER 31, 2023

These days, there are a lot of facial steamers on the market, but you can also DIY at home with a big bowl or sink of warm water and a towel. Robinson says: “Heat and steam are known triggers for many dermatologic conditions, such as rosacea, melasma and eczema.” Visit your nearest Eminence Organics Spa Partner to find out more.

Facials 64

Facials Sebum Hydration Moisturization 64

The Dermatology Digest

JULY 27, 2023

Patricia Farris, MD, Board-Certified Dermatologist, Sanova Dermatology, Metairie, La. So we just don’t have the standardization of what is being eliminated and no consensus as to what should be eliminated based on safety studies. We have lots of experience and long-term safety with petrolatum.

Sustainability 36

Sustainability Skincare Safety Ingredients 36

Aesthetic Advancements Institute (AAI)

JUNE 20, 2023

There is a new dermal filler on the market! Juvéderm’s® newest filler, Volux , has been approved by the FDA and is set to hit medical offices in early 2023. This new filler is designed to specifically target the jawline, an area of concern for many consumers seeking facial sculpting and contouring.

Training 36

Training Injections Medical Facials 36

New Age Spa Institute

DECEMBER 18, 2024

The Clinical Aesthetics Certification is 70 hours of continuing education units (CEU) and ideal for professionals aiming to work in medical spas, dermatology clinics, or with advanced skincare treatments. Licensed estheticians and cosmetologists interested in medspa and advanced modalities.

Medical 52

Medical Esthetics Legal Continuous Education 52